Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2011 Financial Results

Earnings release after close of market, May 3, 2011

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2011 financial results after the Nasdaq market closes on Tuesday, May 3, 2011.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday morning, May 4, 2011 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Participants can access the live conference call by dialing 800-894-5910, (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 800-753-5212 (US) or 402-220-2673 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.